Brief: Cassava Sciences Q3 Basic EPS USD -0.58
07/11/2024 12:55
Nov 07 (Reuters) - Cassava Sciences Q3 net income USD -27.943 million. * Q3 operating income USD -30.623 million * Q3 operating expenses USD 30.623 million
Recent news on Filana Therapeutics
See all newsCassava Sciences says US DOJ has closed investigation into company (updated)
Cassava Sciences rises after US DOJ closes probe into company
Cassava Sciences says US DOJ has closed investigation into company
Brief: Cassava Announces Agreement To Settle Securities Class Action Litigation
Brief: Cassava Sciences Inc - On Dec 15, FDA Places Full Clinical Hold On Cassava's Trial - SEC Filing